Hematology

Clinical pharmacy services in hematology can have a significant impact, and the Pharmacy Times® Hematology resource center provides clinical news and articles about the topic. Here, visitors will find information about upcoming hematology conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
Crizotinib is the first biomarker-driven therapy for relapsed or refractory anaplastic large cell lymphoma in children and young adults.
 
[[thumbnail_alt_text]]
The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct as treatment for patients with multiple myeloma.
[[thumbnail_alt_text]]
The current study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture, which can lead to a heart attack or stroke.
[[thumbnail_alt_text]]
In patients with severe cardiac failure, the extreme emaciation of the body is a potential result and has been termed cardiac cachexia.
[[thumbnail_alt_text]]
In a recent study at the National Institutes of Health, researchers consistently observed signs of damage on the brain scans of patients who died after contracting COVID-19.
[[thumbnail_alt_text]]
Pralatrexate, a lymphoma drug, outperformed remdesivir in treating COVID-19 in a lab experiment. 
 
[[thumbnail_alt_text]]
Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the treatment considerations necessary to properly manage a patient with congenital plasminogen deficiency after she became pregnant.
[[thumbnail_alt_text]]
Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the details of a patient who had a successful pregnancy despite documented infertility due to congenital plasminogen deficiency.
 
[[thumbnail_alt_text]]
The biologics license application lisocabtagene maraleucel in adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies continues to be under regulatory review by the FDA.
[[thumbnail_alt_text]]
The research team designed TETi76 to replicate and amplify the effects of a natural molecule called 2-hydroxyglutarate (2HG), which inhibits the enzymatic activity of TET genes.
[[thumbnail_alt_text]]
CT053, a CAR T-cell therapy, shows a good safety profile and provokes an early and deep response in patients with relapsed and/or refractory multiple myeloma. 

 
[[thumbnail_alt_text]]
Per Morten Sandset, MD, of the University of Oslo and Oslo University Hospital, discusses the disease impact on the gynecologic system and how often patients become infertile due to this impact.